Suppression of antimicrobial peptide expression by Ureaplasma species

Infection and Immunity

Volumn 82, Issue 4, 2014, Pages 1657-1665

  Xiao, Li ^a   Crabb, Donna M ^b   Dai, Yuling ^c   Chen, Yuying ^d   Waites, Ken B ^b   Prescott Atkinson, T ^c  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE PHOSPHATE; ALPHA DEFENSIN 5; ALPHA DEFENSIN 6; BETA DEFENSIN 1; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CYCLIC AMP; INTERLEUKIN 8; PEPTIDES AND PROTEINS; POLYPEPTIDE ANTIBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; FLOW CYTOMETRY; GENE ACTIVATION; GENE EXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HISTONE MODIFICATION; HOST RESISTANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; UREAPLASMA INFECTION; UREAPLASMA PARVUM; UREAPLASMA UREALYTICUM;

ALPHA-DEFENSINS; BETA-DEFENSINS; CELL LINE, TUMOR; CHROMATIN; DNA METHYLATION; DOWN-REGULATION; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; IMMUNITY, INNATE; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; UREAPLASMA; UREAPLASMA INFECTIONS;

EID: 84896468048     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01231-13     Document Type: Article

References (51)

1. Waites KB, Schelonka RL, Xiao L, Grigsby PL, Novy MJ. 2009. Congenital and opportunistic infections: Ureaplasma species and Mycoplasma hominis. Semin. Fetal Neonatal Med. 14:190-199. http://dx.doi.org/10.1016/j.siny.2008.11.009.
2. Viscardi RM, Hasday JD. 2009. Role of Ureaplasma species in neonatal chronic lung disease: epidemiologic and experimental evidence. Pediatr. Res. 65:84R-90R. http://dx.doi.org/10.1203/PDR.0b013e31819dc2f9.
3. Schelonka RL, Waites KB. 2007. Ureaplasma infection and neonatal lung disease. Semin. Perinatol. 31:2-9. http://dx.doi.org/10.1053/j.semperi.2007.01.001.
4. Xiao L, Paralanov V, Glass JI, Duffy LB, Robertson JA, Cassell GH, Chen Y, Waites KB. 2011. Extensive horizontal gene transfer in ureaplasmas from humans questions the utility of serotyping for diagnostic purposes. J. Clin. Microbiol. 49:2818-2826. http://dx.doi.org/10.1128/JCM.00637-11.
5. Paralanov V, Lu J, Duffy LB, Crabb DM, Shrivastava S, Methe BA, Inman J, Yooseph S, Xiao L, Cassell GH, Waites KB, Glass JI. 2012. Comparative genome analysis of 19 Ureaplasma urealyticum and Ureaplasma parvum strains. BMC Microbiol. 12:88. http://dx.doi.org/10.1186/1471-2180-12-88.
6. Reyes L, Reinhard M, Brown MB. 2009. Different inflammatory responses are associated with Ureaplasma parvum-induced UTI and urolith formation. BMC Infect. Dis. 9:9. http://dx.doi.org/10.1186/1471-2334-9-9.
7. Rogan MP, Geraghty P, Greene CM, O'Neill SJ, Taggart CC, McElvaney NG. 2006. Antimicrobial proteins and polypeptides in pulmonary innate defence. Respir. Res. 7:29. http://dx.doi.org/10.1186/1465-9921-7-29.
8. Doss M, White MR, Tecle T, Hartshorn KL. 2010. Human defensins and LL-37 in mucosal immunity. J. Leukoc. Biol. 87:79-92. http://dx.doi.org/10.1189/jlb.0609382.
9. Zasloff M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415:389-395. http://dx.doi.org/10.1038/415389a.
10. Béven L, Wroblewski H. 1997. Effect of natural amphipathic peptides on viability, membrane potential, cell shape and motility of mollicutes. Res. Microbiol. 148:163-175. http://dx.doi.org/10.1016/S0923-2508(97)87647-4.
11. Kuwano K, Tanaka N, Shimizu T, Kida Y. 2006. Antimicrobial activity of inducible human beta defensin-2 against Mycoplasma pneumoniae. Curr. Microbiol. 52:435-438. http://dx.doi.org/10.1007/s00284-005-0215-7.
12. Fassi Fehri L, Wroblewski H, Blanchard A. 2007. Activities of antimicrobial peptides and synergy with enrofloxacin against Mycoplasma pulmonis. Antimicrob. Agents Chemother. 51:468-474. http://dx.doi.org/10.1128/AAC.01030-06.
13. Sang Y, Ortega MT, Blecha F, Prakash O, Melgarejo T. 2005. Molecular cloning and characterization of three beta-defensins from canine testes. Infect. Immun. 73:2611-2620. http://dx.doi.org/10.1128/IAI.73.5.2611-2620.2005.
14. Sang Y, Teresa Ortega M, Rune K, Xiau W, Zhang G, Soulages JL, Lushington GH, Fang J, Williams TD, Blecha F, Melgarejo T. 2007. Canine cathelicidin (K9CATH): gene cloning, expression, and biochemical activity of a novel pro-myeloid antimicrobial peptide. Dev. Comp. Immunol. 31:1278-1296. http://dx.doi.org/10.1016/j.dci.2007.03.007.
15. Lee WH, Zhang J, Zhang YX, Jin Y, Lai R, Zhang Y. 2005. Maximin 9, a novel free thiol containing antimicrobial peptide with antimycoplasma activity from frog Bombina maxima. FEBS Lett. 579:4443-4448. http://dx.doi.org/10.1016/j.febslet.2005.07.010.
16. Wang T, Zhang J, Shen JH, Jin Y, Lee WH, Zhang Y. 2005. Maximins S, a novel group of antimicrobial peptides from toad Bombina maxima. Biochem. Biophys. Res. Commun. 327:945-951. http://dx.doi.org/10.1016/j.bbrc.2004.12.094.
17. Wang L, Yuan Q, Chen S, Cai H, Lu M, Liu Y, Xu C. 2012. Antimicrobial activity and molecular mechanism of the CRES protein. PLoS One 7:e48368. http://dx.doi.org/10.1371/journal.pone.0048368.
18. Hamon MA, Cossart P. 2008. Histone modifications and chromatin remodeling during bacterial infections. Cell Host Microbe 4:100-109. http://dx.doi.org/10.1016/j.chom.2008.07.009.
19. Hamon MA, Batsche E, Regnault B, Tham TN, Seveau S, Muchardt C, Cossart P. 2007. Histone modifications induced by a family of bacterial toxins. Proc. Natl. Acad. Sci. U. S. A. 104:13467-13472. http://dx.doi.org/10.1073/pnas.0702729104.
20. Garcia-Garcia JC, Barat NC, Trembley SJ, Dumler JS. 2009. Epigenetic silencing of host cell defense genes enhances intracellular survival of the rickettsial pathogen Anaplasma phagocytophilum. PLoS Pathog. 5:e1000488. http://dx.doi.org/10.1371/journal.ppat.1000488.
21. Cui W, Taub DD, Gardner K. 2007. qPrimerDepot: a primer database for quantitative real time PCR. Nucleic Acids Res. 35:D805-D809. http://dx.doi.org/10.1093/nar/gkl767.
22. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408. http://dx.doi.org/10.1006/meth.2001.1262.
23. Nuding S, Fellermann K, Wehkamp J, Mueller HA, Stange EF. 2006. A flow cytometric assay to monitor antimicrobial activity of defensins and cationic tissue extracts. J. Microbiol. Methods 65:335-345. http://dx.doi.org/10.1016/j.mimet.2005.08.004.
24. Manimtim WM, Hasday JD, Hester L, Fairchild KD, Lovchik JC, Viscardi RM. 2001. Ureaplasma urealyticum modulates endotoxininduced cytokine release by human monocytes derived from preterm and term newborns and adults. Infect. Immun. 69:3906-3915. http://dx.doi.org/10.1128/IAI.69.6.3906-3915.2001.
25. Peltier MR, Tee SC, Smulian JC. 2008. Effect of progesterone on proinflammatory cytokine production by monocytes stimulated with pathogens associated with preterm birth. Am. J. Reprod. Immunol. 60:346-353. http://dx.doi.org/10.1111/j.1600-0897.2008.00633.x.
26. Taudien S, Groth M, Huse K, Petzold A, Szafranski K, Hampe J, Rosenstiel P, Schreiber S, Platzer M. 2010. Haplotyping and copy number estimation of the highly polymorphic human beta-defensin locus on 8p23 by 454 amplicon sequencing. BMC Genomics 11:252. http://dx.doi.org/10.1186/1471-2164-11-252.
27. Nir-Paz R, Prevost MC, Nicolas P, Blanchard A, Wroblewski H. 2002. Susceptibilities of Mycoplasma fermentans and Mycoplasma hyorhinis to membrane-active peptides and enrofloxacin in human tissue cell cultures. Antimicrob. Agents Chemother. 46:1218-1225. http://dx.doi.org/10.1128/AAC.46.5.1218-1225.2002.
28. Xiao L, Crabb DM, Duffy LB, Paralanov V, Glass JI, Hamilos DL, Waites KB. 2011. Mutations in ribosomal proteins and ribosomal RNA confer macrolide resistance in human Ureaplasma spp. Int. J. Antimicrob. Agents 37:377-379. http://dx.doi.org/10.1016/j.ijantimicag.2010.12.012.
29. Marr AK, Gooderham WJ, Hancock RE. 2006. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr. Opin. Pharmacol. 6:468-472. http://dx.doi.org/10.1016/j.coph.2006.04.006.
30. Alba A, Lopez-Abarrategui C, Otero-Gonzalez AJ. 2012. Host defense peptides: an alternative as antiinfective and immunomodulatory therapeutics. Biopolymers 98:251-267. http://dx.doi.org/10.1002/bip.22076.
31. Lazarev VN, Parfenova TM, Gularyan SK, Misyurina OY, Akopian TA, Govorun VM. 2002. Induced expression of melittin, an antimicrobial peptide, inhibits infection by Chlamydia trachomatis and Mycoplasma hominis in a HeLa cell line. Int. J. Antimicrob. Agents 19:133-137. http://dx.doi.org/10.1016/S0924-8579(01)00479-4.
32. Lazarev VN, Shkarupeta MM, Kostryukova ES, Levitskii SA, Titova GA, Akopian TA, Govorun VM. 2007. Recombinant plasmid constructs expressing gene for antimicrobial peptide melittin for the therapy of mycoplasma and chlamydia infections. Bull. Exp. Biol. Med. 144:452-456. http://dx.doi.org/10.1007/s10517-007-0350-1.
33. Lazarev VN, Shkarupeta MM, Titova GA, Kostrjukova ES, Akopian TA, Govorun VM. 2005. Effect of induced expression of an antimicrobial peptide melittin on Chlamydia trachomatis and Mycoplasma hominis infections in vivo. Biochem. Biophys. Res. Commun. 338:946-950. http://dx.doi.org/10.1016/j.bbrc.2005.10.028.
34. Lazarev VN, Stipkovits L, Biro J, Miklodi D, Shkarupeta MM, Titova GA, Akopian TA, Govorun VM. 2004. Induced expression of the antimicrobial peptide melittin inhibits experimental infection by Mycoplasma gallisepticum in chickens. Microbes Infect. 6:536-541. http://dx.doi.org/10.1016/j.micinf.2004.02.006.
35. Diamond G, Beckloff N, Weinberg A, Kisich KO. 2009. The roles of antimicrobial peptides in innate host defense. Curr. Pharm. Des. 15:2377-2392. http://dx.doi.org/10.2174/138161209788682325.
36. Lai Y, Gallo RL. 2009. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 30:131-141. http://dx.doi.org/10.1016/j.it.2008.12.003.
37. Kallapur SG, Kramer BW, Knox CL, Berry CA, Collins JJ, Kemp MW, Nitsos I, Polglase GR, Robinson J, Hillman NH, Newnham JP, Chougnet C, Jobe AH. 2011. Chronic fetal exposure to Ureaplasma parvum suppresses innate immune responses in sheep. J. Immunol. 187:2688-2695. http://dx.doi.org/10.4049/jimmunol.1100779.
38. Onderdonk AB, Delaney ML, DuBois AM, Allred EN, Leviton A, Extremely Low Gestational Age Newborns (ELGAN) Study Investigators. 2008. Detection of bacteria in placental tissues obtained from extremely low gestational age neonates. Am. J. Obstet. Gynecol. 198:110.e1-110.e7. http://dx.doi.org/10.1016/j.ajog.2007.05.044.
39. Tsunekawa H, Takagi E, Kishimoto H, Shimokata K. 1987. Depressed cellular immunity in Mycoplasma pneumoniae pneumonia. Eur. J. Respir. Dis. 70:293-299.
40. Stelmach I, Podsiadlowicz-Borzecka M, Grzelewski T, Majak P, Stelmach W, Jerzynska J, Poplawska M, Dziadek J. 2005. Humoral and cellular immunity in children with Mycoplasma pneumoniae infection: a 1-year prospective study. Clin. Diagn. Lab. Immunol. 12:1246-1250. http://dx.doi.org/10.1128/CDLI.12.10.1246-1250.2005.
41. Shahzad W, Ajuwape AT, Rosenbusch RF. 2010. Global suppression of mitogen-activated ovine peripheral blood mononuclear cells by surface protein activity from Mycoplasma ovipneumoniae. Vet. Immunol. Immunopathol. 136:116-121. http://dx.doi.org/10.1016/j.vetimm.2010.02.001.
42. Arbibe L, Kim DW, Batsche E, Pedron T, Mateescu B, Muchardt C, Parsot C, Sansonetti PJ. 2007. An injected bacterial effector targets chromatin access for transcription factor NF-kappaB to alter transcription of host genes involved in immune responses. Nat. Immunol. 8:47-56. http://dx.doi.org/10.1038/ni1423.
43. Kida Y, Shimizu T, Kuwano K. 2006. Sodium butyrate up-regulates cathelicidin gene expression via activator protein-1 and histone acetylation at the promoter region in a human lung epithelial cell line, EBC-1. Mol. Immunol. 43:1972-1981. http://dx.doi.org/10.1016/j.molimm.2005.11.014.
44. Assunção P, Antunes NT, Rosales RS, Poveda C, de la Fe C, Poveda JB, Davey HM. 2007. Application of flow cytometry for the determination of minimal inhibitory concentration of several antibacterial agents on Mycoplasma hyopneumoniae. J. Appl. Microbiol. 102:1132-1137. http://dx.doi.org/10.1111/j.1365-2672.2006.03170.x.
45. Assunção P, de la Fe C, Antunes NT, Rosales RS, Ruiz de Galarreta CM, Poveda JB. 2006. Use of flow cytometry for enumeration of Mycoplasma mycoides subsp. mycoides large-colony type in broth medium. J. Appl. Microbiol. 100:878-884. http://dx.doi.org/10.1111/j.1365-2672.2005.02858.x.
46. Assunção P, Diaz R, Comas J, de Galarreta CM, Gonzalez-Llamazares OR, Poveda JB. 2005. Evaluation of Mycoplasma hyopneumoniae growth by flow cytometry. J. Appl. Microbiol. 98:1047-1054. http://dx.doi.org/10.1111/j.1365-2672.2005.02536.x.
47. Mohammadpour HA, Tracy CR, Redelman D, duPre SA, Hunter KW. 2010. Flow cytometric method for quantifying viable Mycoplasma agassizii, an agent of upper respiratory tract disease in the desert tortoise (Gopherus agassizii). Lett. Appl. Microbiol. 50:347-351. http://dx.doi.org/10.1111/j.1472-765X.2010.02800.x.
48. Soehnlen MK, Kunze ME, Karunathilake KE, Henwood BM, Kariyawasam S, Wolfgang DR, Jayarao BM. 2011. In vitro antimicrobial inhibition of Mycoplasma bovis isolates submitted to the Pennsylvania Animal Diagnostic Laboratory using flow cytometry and a broth microdilution method. J. Vet. Diagn. Invest. 23:547-551. http://dx.doi.org/10.1177/1040638711404155.
49. Schmeck B, Lorenz J, N'Guessan PD, Opitz B, van Laak V, Zahlten J, Slevogt H, Witzenrath M, Flieger A, Suttorp N, Hippenstiel S. 2008. Histone acetylation and flagellin are essential for Legionella pneumophilainduced cytokine expression. J. Immunol. 181:940-947.
50. Boeuf P, Vigan-Womas I, Jublot D, Loizon S, Barale JC, Akanmori BD, Mercereau-Puijalon O, Behr C. 2005. CyProQuant-PCR: a real time RT-PCR technique for profiling human cytokines, based on external RNA standards, readily automatable for clinical use. BMC Immunol. 6:5. http://dx.doi.org/10.1186/1471-2172-6-5.
51. Xiao L, Crabb DM, Duffy LB, Paralanov V, Glass JI, Waites KB. 2012. Chromosomal mutations responsible for fluoroquinolone resistance in Ureaplasma species in the United States. Antimicrob. Agents Chemother. 56:2780-2783. http://dx.doi.org/10.1128/AAC.06342-11.